

Match Overview

1	Internet 23 words crawled on 10-Aug-2020 pdf.aminer.org	1%
2	Crossref 13 words Valentina Fanotto, Stefano Cordio, Giulia Pasquini, Caterina Fontanella et al. "Prognostic factors in 868 advanced gastric cancer patients: a retrospective analysis of the Italian Gastric Cancer Registry (IGCR) 2008-2015"	1%
3	Crossref 10 words Erica S. Tsang, Hui-li Wong, Ying Wang, Daniel J. Renouf et al. "Outcomes and Characteristics of Patients Receiving Second-Line Therapy for Advanced Gastric Cancer: A Retrospective Cohort Study"	1%
4	Internet 10 words www.haematologica.org	1%

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 56685

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Real-World Treatment Attrition Rates in Advanced Esophagogastric Cancer

Erica S. Tsang, Howard J. Lim, Daniel J. Renouf, Janine M. Davies, Jonathan M. Loree, Sharlene Gill

Abstract

BACKGROUND

Over the last decade, multiple agents have demonstrated efficacy for advanced



ALL

IMAGES

VIDEOS

15,500,000 Results

Any time ▾

Real-world treatment attrition rates in advanced ...

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.317

There was a high level of treatment attrition, with patients receiving only one line of therapy (n = 73, 43%), two lines (n = 65, 38%), three lines (n = 25, 15%), and four lines (n = 6, 4%). Kaplan-Meier survival analysis demonstrated improved survival with increasing lines of therapy (median overall survival 9.6 vs. 18.5 vs. 25.8 vs. 40.7 months, p < 0.05).

Capecitabine and Oxaliplatin for Advanced Esophagogastric ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa073149>

The cisplatin-fluorouracil regimen is commonly used in the **treatment** of gastric **cancer**, with disappointing results; the 1-year survival **rate** is approximately 30%, ...

Cited by: 2177

Author: David Cunningham, Naureen Starling, S...

Publish Year: 2008

Journal of Clinical Oncology: Vol 38, No 4_suppl

https://ascopubs.org/toc/jco/38/4_suppl?pageStart=4

Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A ...

Howard John Lim's research works | BC Cancer Agency ...

https://www.researchgate.net/scientific-contributions/2125147551_Howard_John_Lim

Howard John Lim's 56 research works with 11 citations and 330 reads, including: **Real-world treatment attrition rates in advanced esophagogastric cancer**.

Heterogeneity of first-line palliative systemic treatment ...

<https://onlinelibrary.wiley.com/doi/10.1002/ijc.32580>

Jul 24, 2019 · Introduction. Palliative **treatment** represents an important part of **esophagogastric**



国内版

国际版

Real-world treatment attrition rates in advanced esophagogastric cancer



Chat with Bing



Sign in



Microsoft Bing

ALL

IMAGES

VIDEOS

13,500,000 Results

Any time ▼

Real-world treatment attrition rates in advanced ...

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.317

There was a high level of treatment attrition, with patients receiving only one line of therapy (**n = 73, 43%**), two lines (**n = 65, 38%**), three lines (**n = 25, 15%**), and four lines (**n = 6, 4%**). Kaplan-Meier survival analysis demonstrated improved survival with increasing lines of therapy (median overall survival 9.6 vs. 18.5 vs. 25.8 vs. 40.7 months, $p < 0.05$).

Author: Erica S. Tsang, Howard John Lim, Da... **Publish Year:** 2020

Real-World Treatment Patterns and Outcomes in Patients ...

<https://link.springer.com/article/10.1007/s12325-020-01394-y> ▼

Jun 12, 2020 · Worldwide, esophageal **cancer** is the ninth most common **cancer** and is the sixth most frequent cause of **cancer**-related death []. In the USA, esophageal cancers were predicted to account for 17,650 new cases and 16,080 deaths in 2019 []. Esophageal cancers are often diagnosed at a relatively late stage and are consequently associated with high mortality; over a third of patients are diagnosed ...

Author: Pranav Abraham, Joe Gricar, Ying Zh... **Publish Year:** 2020

Search Tools

Turn off Hover Translation (关闭取词)



Real-world treatment attrition rates in advanced esophagogastric ca



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

13,500,000 Results

Any time ▾

[Real-world treatment attrition rates in advanced ...](#)

https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.317

There was a high level of treatment attrition, with patients receiving only one line of therapy (n = 73, 43%), two lines (n = 65, 38%), three lines (n = 25, 15%), and four lines (n = 6, 4%). Kaplan-Meier survival analysis demonstrated improved survival with increasing lines of therapy (median overall survival 9.6 vs. 18.5 vs. 25.8 vs. 40.7 months, $p < 0.05$).

Author: Erica S. Tsang, Howard John Lim, Da...

Publish Year: 2020

[Real-World Treatment Patterns and Outcomes in Patients ...](#)

<https://link.springer.com/article/10.1007/s12325-020-01394-y> ▾

Jun 12, 2020 · Worldwide, esophageal **cancer** is the ninth most common **cancer** and is the sixth most frequent cause of **cancer**-related death [1]. In the USA, esophageal cancers were predicted to account for 17,650 new cases and 16,080 deaths in 2019 [2]. Esophageal cancers are often diagnosed at a relatively late stage and are consequently associated with high mortality; over a third of patients are diagnosed ...

Author: Pranav Abraham, Joe Gricar, Ying Zh...

Publish Year: 2020

[Journal of Clinical Oncology: Vol 38, No 4_suppl](#)

https://ascopubs.org/toc/jco/38/4_suppl?pageStart=4

Real-world treatment attrition rates in advanced esophagogastric cancer. Tsang et al. pp. 317. ...
Economic impacts of care by high-volume providers for noncurative **esophagogastric cancer**: A population-based analysis. ... **Real-world** efficacy and biomarker of nivolumab for **advanced** gastric **cancer**.

[Howard John Lim's research works | BC Cancer Agency ...](#)

https://www.researchgate.net/scientific-contributions/2125147551_Howard_John_Lim

Howard John Lim's 56 research works with 11 citations and 330 reads, including: **Real-world treatment attrition rates in advanced esophagogastric cancer**.

[Erica S. Tsang's research works | BC Cancer Agency ...](#)

https://www.researchgate.net/scientific-contributions/2143975115_Erica_S_Tsang

Erica S. Tsang's 16 research works with 6 citations and 307 reads, including: **Real-world treatment attrition rates in advanced esophagogastric cancer**.